Trial Profile
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Prexasertib (Primary)
- Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Jun 2023 Results of exploratory analysis assessing the role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in ovarian cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2023 Results of preliminary analysis(n=49 of biopsy cohort: n=25 and non-biopsy cohort: n=24) assessing biomarker analysis of prexasertib in BRCA wild-type platinum-resistant recurrent, high-grade serous ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research
- 11 Aug 2022 Status changed from completed to discontinued (Eli Lilly prematurely terminated the study)